DexCom, Inc. (FRA:DC4)

Market Cap	23.87B -28.3%
Revenue (ttm)	3.97B +15.6%
Net Income	712.28M +45.1%
EPS	1.78 +46.7%
Shares Out	n/a
PE Ratio	33.52
Forward PE	28.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33
Average Volume	187
Open	61.42
Previous Close	61.34
Day's Range	61.37 - 61.82
52-Week Range	46.88 - 86.71
Beta	n/a
RSI	59.21
Earnings Date	Feb 12, 2026

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1999
• Employees: 11,050
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DC4

Financial Performance

In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.

Financial numbers in USD